{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:22:48Z","timestamp":1762179768352,"version":"build-2065373602"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T00:00:00Z","timestamp":1299715200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:p>\n                    <jats:bold>OBJECTIVES:<\/jats:bold>\n                    To compare the brain anticholinergic activities of five urinary spasmolytic drugs (USDs).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    In vitro study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Laboratory.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>PARTICIPANTS:<\/jats:bold>\n                    None.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>MEASUREMENTS:<\/jats:bold>\n                    A validated 96\u2010well anticholinergic radio receptor bioassay using small incubation volumes (240\u2003\u03bcL per well) was applied in the current study. The different USDs (tolterodine, oxybutynin, solifenacin, darifenacin, and 5\u2010hydroxy\u2010methyl\u2010tolterodine (5\u2010HMT; the active metabolite of fesoterodine) were dissolved in plasma in their respective therapeutic concentration ranges. The plasma samples were added directly to the wells of 96 filter plates, wherein the incubation, filtration, and counting of undisplaced radioactivity was performed. Standard curves with atropine were used as reference for estimations of anticholinergic activity (AA).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    5\u2010HMT and tolterodine displayed the highest AA of the tested USDs. In the middle of the therapeutic concentration range, the central anticholinergic potency of 5\u2010HMT and tolterodine was more than 10 times as high as that of oxybutynin, solifenacin, and darifenacin. Darifenacin exhibited the lowest AA at therapeutic serum concentrations (&lt;one\u2010third the AA of oxybutynin and solifenacin).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    Tolterodine and fesoterodine appear to have the highest pharmacodynamic potential to induce central anticholinergic side effects of the tested USDs. Darifenacin displayed the lowest AA, and combined with a low degree of brain distribution, it has probably the most favorable pharmacological profile of the USDs with respect to risk of cognitive impairment in older adults.\n                  <\/jats:p>","DOI":"10.1111\/j.1532-5415.2010.03307.x","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T10:25:49Z","timestamp":1299752749000},"page":"501-505","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of Brain Anticholinergic Activities of Urinary Spasmolytic Drugs Using a High\u2010Throughput Radio Receptor Bioassay"],"prefix":"10.1111","volume":"59","author":[{"given":"Stine Mj\u00e5vatn","family":"Jakobsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hege","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017161"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02377.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199915010-00002"},{"key":"e_1_2_6_5_2","first-page":"1481","article-title":"The Anticholinergic Drug Scale as a measure of drug\u2010related anticholinergic burden","volume":"46","author":"Carnahan RM","year":"2006","journal-title":"Associations with serum anticholinergic activity"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200506000-00013"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1980.01780160063007"},{"key":"e_1_2_6_8_2","first-page":"198","article-title":"Serum anticholinergic activity in a community\u2010based sample of older adults","volume":"60","author":"Mulsant BH","year":"2003","journal-title":"Relationship with cognitive performance"},{"key":"e_1_2_6_9_2","first-page":"1792","article-title":"Preserving cognitive function for patients with overactive bladder","volume":"62","author":"Kay GG","year":"2008","journal-title":"Evidence for a differential effect with darifenacin"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02449.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1532-5415.2002.50281.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.11.1318-a"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200312043492325"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01737.x"},{"key":"e_1_2_6_15_2","first-page":"8","article-title":"Identification of medications that cause cognitive impairment in older people","volume":"46","author":"Katz IR","year":"1998","journal-title":"The case of oxybutynin chloride"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.014"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01680.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.03.057"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903260790"},{"key":"e_1_2_6_20_2","first-page":"14","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome","volume":"4","author":"Wagg A","year":"2006","journal-title":"A pooled analysis"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-3806(95)01515-9"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001270"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn992"},{"key":"e_1_2_6_24_2","first-page":"519","article-title":"Delirium episode as a sign of undetected dementia among community dwelling elderly subjects","volume":"69","author":"Rahkonen T","year":"2000","journal-title":"A 2 year follow up study"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/28.6.551"},{"key":"e_1_2_6_26_2","first-page":"142","article-title":"The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction","volume":"112","author":"Yoshida A","year":"2010","journal-title":"Bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0648-1"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645040-00001"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5565(96)00158-1"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200504000-00009"},{"key":"e_1_2_6_31_2","first-page":"1707","article-title":"Flaws in the serum anticholinergic activity assay","volume":"57","author":"Cox EA","year":"2009","journal-title":"Implications for the study of delirium"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1532-5415.2010.03307.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1532-5415.2010.03307.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:33:56Z","timestamp":1762176836000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1532-5415.2010.03307.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1532-5415.2010.03307.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1532-5415.2010.03307.x","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"type":"print","value":"0002-8614"},{"type":"electronic","value":"1532-5415"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}